Under Armour bets on lower input costs to raise profit view as sales lag
FILE PHOTO: People walk by an Under Armour store in Manhattan, New York City, U.S., February 7, 2022. REUTERS/Andrew Kelly/File Photo
By Annett Mary Manoj
(Reuters) -Apparel maker Under Armour raised its annual profit and margin forecasts on Thursday, betting that easing input and freight costs would help offset weak demand in North America, sending its shares up 6%.
The company is leaning on lower production costs to drive up profit at a time when demand for its apparel and footwear has slowed despite heavy discounts to customers holding back on spending due to elevated inflation.
Lower spending led to a third straight quarter of decline in sales in its largest North America market and the company missed market expectations for third-quarter sales.
It has also seen a hit from wholesalers such as Dick's Sporting Goods and Foot Locker reducing orders in the United States.
Wholesale revenue fell 13% while direct-to-consumer (DTC) revenue rose 4% in the quarter, as deeper promotions helped pull in more customers in this channel.
"(Gross margins) are going to be better in this current fiscal year...but the problem is that Under Armour has been around the same sales level for several years," Morningstar analyst David Swartz said.
Under Armour now expects annual gross margin to be up 120 to 130 basis points and forecast a profit of 57 cents to 59 cents per share for fiscal 2024, compared to prior forecast of 47 cents to 51 cents.
However, CFO David Bergman warned of "a little bit" of impact on gross margin from promotions.
Its third-quarter revenue of $1.49 billion missed LSEG estimates of $1.50 billion, while adjusted profit of 19 cents topped expectations of 11 cents.
(Reporting by Annett Mary Manoj and Ananya Mariam Rajesh in Bengaluru; Editing by Arun Koyyur)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qualcomm investor day to detail data center plans Wednesday
- BIO CEO says more consistency needed in FDA review process
- Exclusive: Webull launches private market SPVs for late-stage company access
Create E-mail Alert Related Categories
General News, ReutersRelated Entities
Morningstar, Inc.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share